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Background: Nintedanib has anti-fibrotic and anti-inflammatory activity and is approved for the treat-
ment of idiopathic pulmonary fibrosis. The aim of this study was to noninvasively assess the efficacy
of nintedanib in a mouse model of partial lung irradiation to prevent radiation-induced lung damage
(RILD).
Methods: 266 C57BL/6 adult male mice were irradiated with a single radiation dose (0, 4, 8, 12, 16 or
20 Gy) using parallel-opposed fields targeting the upper right lung using a precision image-guided small
animal irradiator sparing heart and spine based on micro-CT images. One week post irradiation, mice
were randomized across nintedanib daily oral gavage treatment (0, 30 or 60 mg/kg). CT density analysis
of the lungs was performed on monthly acquired micro-CT images. After 39 weeks, lungs were processed
to evaluate the fibrotic phenotype.
Results: Although the CT density increase correlated with the radiation dose, nintedanib did not influence
this relationship. Immunohistochemical analysis confirmed the ability of nintedanib to reduce the micro-
scopic fibrotic phenotype, in particular interstitial edema, interstitial and perivascular fibrosis and
inflammation, and vasculitis.
Conclusions: Nintedanib reduces radiation-induced lung fibrosis after partial lung irradiation without
adverse effects, however, noninvasive CT imaging measuring electron density cannot be applied for mon-
itoring its effects.
 2017 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 124 (2017) 482–487Clinically relevant radiation-induced lung damage (RILD) occurs
in 5–15% of patients who undergo radiation therapy of the chest to
treat lung cancer, but also breast cancer, lymphomas and other
cancers. RILD presents as an inflammation of the lungs and
depends on the dose of irradiation used and the amount of lung tis-
sue irradiated [1]. RILD is a dose-limiting side effect of irradiation
and is a major dose-limiting toxicity [2]. Dose-volumemetrics such
as the mean lung dose and the percentage of lung volume receiving
a dose of 20 Gy or more (V20) are associated with pneumonitis, but
their predictive value remains low [3]. Computed tomography (CT)imaging of lung characteristics may contribute to the prediction of
pneumonitis and fibrosis and the quest for robust genetic predic-
tors continues [4,5].
Nintedanib is an oral small molecule receptor TKI targeting vas-
cular endothelial growth factor receptor (VEGFR) 1–3, fibroblast
growth factor receptor (FGFR) 1–3 and platelet-derived growth fac-
tor receptor (PDGF) alpha and beta. Nintedanib in combination
with docetaxel is approved for the treatment of locally advanced,
metastatic, or locally recurrent lung adenocarcinoma after failure
of first-line treatment [6]. Nintedanib is also approved for the
treatment of patients with idiopathic pulmonary fibrosis (IPF) that
is characterized by progressive fibrosis of the lung parenchyma [7].
Nintedanib interferes with central processes in fibrosis such as
fibroblast proliferation, migration and differentiation, and the
secretion of extracellular matrix proteins [8]. Moreover, nintedanib
has shown consistent anti-fibrotic and anti-inflammatory activity
in animal models of lung fibrosis [9]. Retrospective studies
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factor for the development of severe radiation pneumonitis [10].
The aim of the present study was to explore the potential
efficacy (quantitative non-invasive CT imaging and semi-
quantitative histology as primary and secondary endpoint, respec-
tively) and tolerability of nintedanib in reducing lung fibrosis in a
mouse model of RILD.Materials and methods
Endpoints
The primary endpoint of the study was quantitative non-
invasive CT imaging of fibrosis development and the secondary
endpoint was semi-quantitative histology for fibrosis 39 weeks
post irradiation.General study design
Adult C57Bl/6 male mice (n = 266) were irradiated with a single
fraction radiation dose of 0, 4, 8, 12, 16 or 20 Gy using 5-mm circu-
lar parallel-opposed fields (225 kVp, with 0.3 mm added Cu filtra-
tion) targeting the upper right lung with a precision image-guided
small animal irradiator (XRAD-225Cx, PXI Inc, North Branford, CT,
USA) sparing heart and spine based on micro-CT (80 kVp, 2.5 mA,
with 2 mm added Al filtration) images from an integrated imaging
panel, acquired at a resolution of 100 mm. Irradiation and imaging
protocols, dose calculations, deformable registration and image
analysis have been previously described in detail [11]. Mice were
randomized and one week after irradiation, nintedanib was admin-
istered once daily (0, 30 or 60 mg/kg) by oral gavage, for a total of
39 weeks (Suppl. Table 1). Micro-CT imaging to assess changes in
electron density was repeated on a monthly basis with in total
10 imaging sessions resulting in a cumulative skin dose of approx-
imately 39 cGy. Animals were monitored on a daily basis for signs
of compromised health and were weighted before the start of each
imaging session. At the end of the experiment, lungs were removed
and processed for histological evaluation of the fibrotic phenotype.
The general design of the study is outlined in Fig. 1. The study was
approved by the Animal Ethical Committee of the University of
Maastricht (number 2012-006).Immunohistochemical staining and analysis
Five-micrometer thick sections were deparaffinized and rehy-
drated to distilled water. Sections were routinely stained for hema-
toxylin and eosin (H&E) by consecutive incubation with
hematoxylin (10 min, Klinipath), warm tapwater (10 min), distilled
water wash and eosin solution (3–5 min, VWR). Sections were
stained for collagen using a Masson’s trichrome stain (Sigma–
Aldrich) withWeigert’s iron hematoxylin (10 min), warm tap water
(10 min), distilled water wash followed by a Biebrich scarlet-acid
fuchsin stain (10–15 min), distilled water wash followed by
differentiation in phosphomolybdic–phosphotungstic acid solution
(10–15 min), aniline blue solution (5–10 min), a rinse in distilled
water and 1% acetic acid solution (2–5 min). Consecutive sectionsFig. 1. Study design.were additionally stained for fibrin using an elastic Von Giesson
stain (Sigma–Aldrich) with elastic stain solution (10 min), a rinse
in deionized water followed by differentiation in ferric chloride
solution, a rinse in tapwater, 95% alcohol, deionizedwater followed
by van Giesson solution (1–3 min). All sections were dehydrated to
xylene through different alcohol incubations and mounted with
resinous mounting medium.
All sections were analyzed in a blinded manner by an experi-
enced lung pathologist (BioGenetics Research Laboratories, Inc.,
P.S., WA, USA) and scored for (1) alveolar wall thickness, (2) inter-
stitial edema, (3) interstitial fibrosis and inflammation, (4) peri-
bronchial fibrosis and inflammation, (5) perivascular fibrosis and
inflammation, (6) increased alveolar macrophages, (7) increased
interstitial macrophages, (8) atelectasis (multifocal), (9) alveolar
proteinaceous debris (resolved edema), (10) vasculitis (lymphohis-
tiocytic), (11) lymphoid nodules (peribronchiolar), (12) foreign
body, pneumonia, (13) bronchioloalveolar adenoma, (14) lym-
phoreticular infiltration (perivascular), (15) artery tunica media
degeneration and (15) bronchioloalveolar carcinoma. The severity
of microscopic lesions in each tissue section was graded subjec-
tively from 0 to 4. Grade 0 was indicative for no lesion or normal
tissue morphology. Grade 1 indicated minimal histological changes
and used for processes where <10% of the tissue was involved.
Grade 2 was used for mild histological changes, noticeable but
not prominently present in 11–20% of the involved tissue. Grade
3 indicated moderate histological changes and used for the pro-
cesses in which 21–40% of the tissue was involved. Grade 4 was
used for marked, overwhelming histological changes for processes
where between 41% and 100% of the tissue was involved [12–14].Results
Irradiation could be adequately targeted to the right upper lung
with sparing of the rest of the chest organs. Dose calculations in the
80% to max irradiated lung region performed with the in house
developed validated small animal treatment planning system
SmART-Plan [15] for the different irradiation dose groups resulted
in similar doses (Suppl. Table 2) between the nintedanib treatment
arms and will be referred at as 4, 8, 12, 16 and 20 Gy. The pre-
scribed dose was reached in 9 ± 2% of the total lung volume. Both
the irradiation alone and the combination of irradiation with nin-
tedanib treatment were well tolerated. No weight loss was
observed and in most cohorts weight increased with age (Fig. 2
and Suppl. Fig. 1). Mortality was observed in 9.9% of the animals,
but was completely attributed to application issues during oral
gavage, mainly in the first month after the start of compound
administration.
CT analysis indicated a dose- and time dependent increase of the
lung density in the irradiated area of the right lung, in agreement
with the observed pathological characteristics [16]. However, this
dose- and time dependent increase of the lung density could not
be delayed neither reduced by nintedanib (Fig. 3A and B). A signif-
icant (p < 0.001) increase in difference between the irradiated and
the non-irradiation area of the right lung (delta CT) was observed
when comparing 20 Gy with sham-irradiated animals. No signifi-
cant differences were observed in CT density between the different
nintedanib treatment groups with the same radiation dose.
Histological examination of lungs treated with the highest irra-
diation dose of 20 Gy showed as most obvious findings elevated
diffuse alveolar damage, an increase of the alveolar wall thickness,
increased alveolar and interstitial macrophages and multifocal
atelectasis (Table 1). Additionally, mild interstitial edema,
interstitial and perivascular fibrosis and inflammation, alveolar
proteinaceous debris, lymphohistiocytic vasculitis, perivascular
lymphoreticular infiltration and perivascular artery tunica media
Fig. 2. Changes in relative body weight during the course of the experiment for the indicated experiments. Data (black dots) represent the average of at least 12 individual
(Grey) animals.
Fig. 3. (A) Representative micro-CT thorax images and (B) effect of nintedanib on the CT density over time of un-irradiated (full lines) and irradiated (20 Gy; dashed lines)
animals for 0, 30 or 60 mg/kg nintedanib treatment. (C) Representative Masson’s trichrome stainings of the affected lung area 39 weeks after irradiation (20 Gy) treated with
0, 30 or 60 mg/kg nintedanib. Collagen is stained in blue, nuclei are purple and cytoplasm is pink. Data represent the mean ± standard deviation of at least 12 individual
animals.
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Table 1
Average semi-quantitative histological score of the irradiated lung area 39 weeks after irradiation for 14 different pathological characteristics.
Nintedanib (mg/kg) 0 30 60
Radiation dose (Gy) 0 4 8 12 16 20 0 4 8 12 16 20 0 4 8 12 16 20
Alveolar wall thickness 0.6 0 1.0 1.1 1.1 1.3 0.8 0.7 0.9 1.1 0.9 1.0 0.7 1.0 0.9 1.1 0.9 1.4
Interstitial edema 0 0 0 0 0 0.5 0 0 0 0 0 0 0 0.1 0 0 0 0.3
Interstitial fibrosis and inflammation 0 0 0 0 0.2 0.2 0 0 0 0 0 0 0 0 0 0 0 0
Perivascular fibrosis and inflammation 0 0 0 0 0.2 0.2 0 0 0 0 0 0 0 0 0 0 0 0
Increased alveolar macrophages 0.7 0.3 1.0 1.2 0.9 1.5 0.6 0.7 0.9 1.1 0.9 1.0 1.0 1.0 0.7 1.2 0.9 1.5
Increased interstitial macrophages 1.2 0 1.0 1.0 1.1 1.5 0.8 0.7 0.9 1.1 0.9 1.0 1.0 0.9 0.7 1.2 0.9 1.6
Multifocal, atelectasis 1.2 1.3 1.5 1.1 1.1 1.4 0.8 0.8 0.9 1.1 0.9 1.0 0.9 1.1 0.9 1.4 1.1 1.3
Alveolar proteinaceous debris, resolved edema 0.3 0 0 0.2 0.1 0.5 0 0 0 0 0 0 0 0 0 0.1 0 0.1
Vasculitis, lymphohistiocytic 0 0 0 0.5 0.3 0.9 0 0.3 0.1 0 0 0 0 0 0 0 0 0
Lymphoid nodules, peribronchiolar 0.3 0 0.1 0.2 0 0 0 0.1 0 0 0.1 0.3 0.2 0.4 0.1 0.5 0.1 0.6
Foreign body inhalation, pneumonia 0 0 0 0 0 0 0 0 0 0 0.1 0 0.3 0 0 0 0 0.3
Bronchioloalveolar adenoma 0 0 0 0 0 0 0 0.1 0.1 0 0 0 0 0 0 0 0 0
Lymphoreticular infiltration, perivascular 0 0 0.7 0.3 0.2 0.3 0.7 0 0.3 0.7 0.4 0.2 0.4 0.8 0.6 0.9 0.4 1.0
Artery tunica media degeneration 0 0 0 0 0 0.3 0 0 0 0 0 0 0 0 0 0 0 0
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tial fibrosis and inflammation, perivascular fibrosis and inflamma-
tion, alveolar proteinaceous debris, resolved edema, vasculitis and
lymphohistiocytic infiltrations. This effect was observed at 30 mg/
kg and at 60 mg/kg doses, without striking differences between the
two dosages (Fig. 3C and Table 1). As expected from its working
mechanism, nintedanib did not affect alveolar wall thickness and
macrophage involvement. At the higher dose of 60 mg/kg, ninteda-
nib seems to augment peribronchiolar lymphoid nodules and lym-
phoreticular infiltration (Table 2).
Discussion
Radiation-induced lung damage (RILD) is a dose-limiting toxic-
ity for high-dose radiotherapy of lung cancer [1–3]. It is a multifac-
torial process that involves a cascade of cytokines and growth
factors, including repair and migration of many cells in the lungs
and its vasculature [1]. Recently, it has also become established
that the heart and the lungs are integral functional organs that
should be considered together to understand RILD in more detail
[17,18]. Genetic factors as well as life-style such as smoking and
the characteristics of the lungs all have a role in the susceptibility
and the severity of RILD [1–3].
At present, no specific preventive medication or treatment for
RILD is available. Amifostine was shown to prevent RILD in preclin-
ical experiments as well as in human studies, but due to concerns
of tumor protection and side effects, this medication has not beenTable 2
Differences in histological score of Table 1 of the affected lung area 39 weeks after treatme
and 60 mg/kg.
Nintedanib D30
Radiation dose (Gy) 0 4 8 12
Alveolar wall thickness 0.2 0.7 0.1 0.0
Interstitial edema 0.0 0.0 0.0 0.0
Interstitial fibrosis and inflammation 0.0 0.0 0.0 0.0
Perivascular fibrosis and inflammation 0.0 0.0 0.0 0.0
Increased alveolar macrophages 0.1 0.4 0.1 0.
Increased interstitial macrophages 0.4 0.7 0.1 0.1
Multifocal, atelectasis 0.4 0.5 0.6 0.0
Alveolar proteinaceous debris, resolved edema 0.3 0.0 0.0 0.
Vasculitis, lymphohistiocytic 0.0 0.3 0.1 0.
Lymphoid nodules, peribronchiolar 0.3 0.1 0.1 0.
Foreign body inhalation, pneumonia 0.0 0.0 0.0 0.0
Bronchioloalveolar adenoma 0.0 0.1 0.1 0.0
Lymphoreticular infiltration, perivascular 0.7 0.0 0.4 0.4
Artery tunica media degeneration 0.0 0.0 0.0 0.0
A reduction in the pathologic score is depicted as negative value and an aggravation asapproved for this indication [19]. Rodent studies and retrospective
series in patients suggest that captopril, an angiotensin-converting
enzyme (ACE) inhibitor attenuating cardio-pulmonary radiation
damage [17,18], may mitigate RILD through its effects on the heart,
the blood vessels and repair mechanisms [18,20]. Unfortunately, a
prospective trial in non-small cell cancer (NSCLC) patients investi-
gating captopril has been closed early due to lack of accrual [21].
Imatinib, a small molecule receptor tyrosine kinase inhibitor
(TKI), targeting the platelet-derived growth factor receptors
(PDGFR) alpha and beta and the stem cell factor receptor c-Kit,
reduced radiation-induced lung fibrosis in mice with only limited
effects against acute inflammation [22]. Strategies that mitigate
RILD in experimental models include stem cell therapy, cyclo-
oxygenase (COX)-2 inhibitors, imatinib and captopril, but none of
them have been introduced in standard practice [18,21–23]. A drug
that could both have a beneficial effect on NSCLC and prevent RILD
would be of obvious value.
In the present study, we have shown that nintedanib, a receptor
TKI approved for the treatment of metastatic NSCLC and IPF,
reduced radiation-induced fibrosis, interstitial edema and vasculi-
tis in a preclinical model of RILD, independent of the tested dosage.
As nintedanib interferes with central processes in fibrosis such as
fibroblast proliferation, migration and differentiation, and the
secretion of extracellular matrix proteins, the findings of our pre-
clinical study are consistent with the mode of action of nintedanib
[8]. Also consistent with its mode of action, nintedanib did not
affect alveolar wall thickness and macrophage involvement. Asnt between the control group and the treatment groups with nintedanib at 30 mg/kg
D60
16 20 0 4 8 12 16 20
0.2 0.3 0.1 1,0 0.1 0.0 0.2 0.1
0.0 0.5 0.0 0.1 0.0 0.0 0.0 0.2
0.2 0.2 0.0 0.0 0.0 0.0 0.2 0.2
0.2 0.2 0.0 0.0 0.0 0.0 0.2 0.2
1 0.0 0.5 0.3 0.7 0.3 0.0 0.0 0.0
0.2 0.5 0.2 0.9 0.3 0.2 0.2 0.1
0.2 0.4 0.3 0.2 0.6 0.3 0.0 0.1
2 0.1 0.5 0.3 0.0 0.0 0.1 0.1 0.4
5 0.3 0.9 0.0 0.0 0.0 0.5 0.3 0.9
2 0.1 0.3 0.1 0.4 0.0 0.3 0.1 0.6
0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.3
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
0.2 0.1 0.4 0.8 0.1 0.6 0.2 0.7
0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3
positive value.
486 Nintedanib in radiation fibrosisexpected with the used doses, the drug, which was given once daily
for 9 months, was very well tolerated. This may be related to the
delivery of a highly localized radiation dose with a high-precision,
X-ray guided small animal irradiation device. The radiation dose
distribution therefore is a better approximation to that in patients
and could spare the vast majority of the lung and the heart. This
contrasts to most preclinical studies for RILD, in which the whole
chest or the hemi-thorax was irradiated. As RILD is clearly affected
by the volume of the irradiated lung and the heart, we believe that
our experimental set-up may be more reliable as a step towards
testing an intervention in humans [24].
Lung irradiation studies in mice indicate that pneumonitis and
fibrosis can be dissociated from each other and that radiation-
induced fibrosis can and does occur without a preceding inflamma-
tory event [25]. Therefore, the selection of the mouse strain in
pre-clinical RILD research is important since striking strain-
related differences are found in radiation sensitivity of the mouse
lung [26]. For example, C57BL/6 mice, which are prone to
radiation-induced fibrosis, develop less inflammation than C3H
mice, which are susceptible to radiation-induced pneumonitis.
Conversely, the inflammation-susceptible mice develop less fibro-
sis than the fibrosis-prone mice [25,26]. It has been demonstrated
that for example glucocorticoids can reduce inflammation but not
subsequent fibrosis in the lungs of irradiated animals [26]. In addi-
tion, although pneumonitis mostly occurs within the irradiated
areas of the lung, it may spread to non-irradiated areas, indicating
the involvement of cytokines [1]. It has been hypothesized that
radiation depletes critical target cells in the lung, which initiates
pneumonitis and/or fibrosis. A major effort has been mounted to
identify these targets with the intention of protecting them from
radiation damage and thereby preventing or at least minimizing
the severity of radiation-induced pneumonitis and fibrosis without
compromising tumor cell kill and tumor control. The two most
likely candidate target cells are thought to be the type II cells
(release of surfactant into alveolus) and the vascular endothelial
cells (release of surfactant in blood serum) in a network with
fibroblasts, macrophages and lymphocytes. Radiation prompts
the release of soluble mediators, such as cytokines (e.g. TGFb,
TNFa, TNFb, IL-1, IL-2) and growth factors (e.g. PDGF, FGF), which
deliver the message between the different cells eventually result-
ing in the pathology of radiation pneumonitis and fibrosis [1].
Pro-fibrotic macrophages producing TGF-b and IL-13 have been
shown to be predominant in lungs of IPF patients [27]. Immune
dysregulation has been considered, at least, as a collateral mecha-
nism in the pathogenesis of IPF [28], in line with the immunosup-
pressive effects of radiation through regulation of TGF-b producing
pro-fibrotic macrophages [29]. Nintedanib affects various molecu-
lar signaling pathways implicated in the pathogenesis and progres-
sion of fibrosis [8]. Animal models of lung fibrosis have been used
to demonstrate that nintedanib has a preventive and therapeutic
anti-fibrotic effect [9]. In vitro studies suggest that nintedanib
exerts its anti-fibrotic activity by inhibiting fibroblast proliferation,
migration, transformation and contraction [8,30]. Recently, ninte-
danib was shown to attenuate pro-fibrotic mediator release from
T cells [31] and differentiation of alternatively activated macro-
phages [32]. These data suggest that the anti-fibrotic effect of nin-
tedanib may be elicited directly by attenuating fibroblast functions
or indirectly through the immune system.
Our histological results support the testing of nintedanib in
patients irradiated for lung cancer. Two clinical trials testing this
hypothesis are currently ongoing (NCT02496585, NCT02452463).
However, nintedanib did not affect CT density. This could be
explained by the fact that CT density is mostly defined by alveolar
wall thickness and macrophage infiltration, characteristics which
were not affected by nintedanib. Our data suggest that non-
invasive CT imaging to monitor efficacy of anti-fibrotic agents isnot recommended. FDG-PET imaging could be an alternative to
assess inflammation and fibrosis, since a recent study has shown
that FDG lung uptake may be used to assess IPF severity and to pre-
dict progression-free survival in these patients [33]. The increased
uptake found in IPF patients might be related to a metabolic shift
towards increased glycolysis, particularly in fibroblasts [34]. This
consistent increase in FDG-PET signal however does not seem to
align with the fluctuating macrophage infiltration patterns after
irradiation [35], emphasizing the need for better alternatives. Our
study nevertheless provides further rationale to investigate ninte-
danib to reduce radiation-induced fibrosis, not only in the lung, but
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